Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00089258
Recruitment Status : Completed
First Posted : August 5, 2004
Last Update Posted : January 17, 2013
National Cancer Institute (NCI)
Information provided by:
Memorial Sloan Kettering Cancer Center

Brief Summary:

RATIONALE: Monoclonal antibodies, such as monoclonal antibody 3F8, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Beta-glucan, isotretinoin, and sargramostim may increase the effectiveness of monoclonal antibody 3F8 by making tumor cells more sensitive to the monoclonal antibody. Combining different types of biological therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving beta-glucan, isotretinoin, and sargramostim together with monoclonal antibody 3F8 works in treating patients with neuroblastoma that has not responded to previous treatment.

Condition or disease Intervention/treatment Phase
Neuroblastoma Biological: beta-glucan Biological: monoclonal antibody 3F8 Biological: sargramostim Drug: isotretinoin Phase 2

Detailed Description:


  • Determine the efficacy of beta-glucan, isotretinoin, and sargramostim (GM-CSF) in enhancing monoclonal antibody 3F8-mediated ablation in patients with high-risk refractory neuroblastoma.
  • Determine the antitumor activity of this regimen, in terms of assessing disease status in the bone marrow by real-time quantitative reverse transcription polymerase chain reaction, in these patients.
  • Determine the toxicity of this regimen in these patients.

OUTLINE: This is an open-label study. Patients are stratified according to refractory disease (primary refractory [never had disease progression or disease recurrence] vs secondary refractory [recurrent disease that did not respond completely to reinduction therapy]).

  • Courses 1 and 2: Patients receive sargramostim (GM-CSF) subcutaneously once daily on days -5 to 11. Patients also receive oral beta-glucan once daily on days -2 to 11 and monoclonal antibody (MOAB) 3F8 IV over 30-90 minutes on days 0-4 and 7-11.
  • Courses 3 and 4: Patients receive GM-CSF, beta-glucan, and MOAB 3F8 as above. Patients also receive oral isotretinoin twice daily on days -2 to 11.

Treatment repeats every 2-4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 2 years.

PROJECTED ACCRUAL: A total of 27-74 patients (10-33 for stratum 1 and 17-41 for stratum 2) will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 74 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Anti-GD2 3F8 Antibody and Biologic Response Modifiers for High-risk Neuroblastoma
Study Start Date : July 2004
Actual Primary Completion Date : November 2006

Primary Outcome Measures :
  1. Disease response as assessed by PT-PC at the end of 4 courses

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of neuroblastoma, as defined by 1 of the following:

    • Histologically confirmed disease
    • Bone marrow metastases plus high urine catecholamines
  • High-risk disease meeting 1 of the following stage criteria:

    • Stage IV, with 1 of the following:

      • Any age with MYCN amplification
      • > 18 months of age without MYCN amplification
    • Stage III, with both of the following:

      • Any age with MYCN amplification
      • Unresectable disease
    • Stage 4S with MYCN amplification
  • Measurable or evaluable soft tissue disease
  • Relapsed disease resistant to standard induction chemotherapy and salvage therapy



  • Any age

Performance status

  • Not specified

Life expectancy

  • Not specified


  • Not specified


  • No severe hepatic toxicity ≥ grade 3


  • No severe renal toxicity ≥ grade 3


  • No severe cardiac toxicity ≥ grade 3


  • No severe pulmonary toxicity ≥ grade 3


  • Not pregnant
  • Negative pregnancy test
  • No severe neurologic toxicity ≥ grade 3
  • No severe gastrointestinal toxicity ≥ grade 3
  • No other severe major organ dysfunction except ototoxicity
  • No history of allergy to mouse proteins
  • No active life-threatening infection
  • No human anti-mouse antibody titer > 1,000 ELISA units/mL


Biologic therapy

  • Not specified


  • See Disease Characteristics

Endocrine therapy

  • Not specified


  • Not specified


  • Not specified

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00089258

Layout table for location information
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Nai-Kong V. Cheung, MD, PhD Memorial Sloan Kettering Cancer Center
Layout table for additonal information Identifier: NCT00089258    
Other Study ID Numbers: 04-050
First Posted: August 5, 2004    Key Record Dates
Last Update Posted: January 17, 2013
Last Verified: January 2013
Keywords provided by Memorial Sloan Kettering Cancer Center:
localized unresectable neuroblastoma
disseminated neuroblastoma
regional neuroblastoma
stage 4S neuroblastoma
recurrent neuroblastoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Dermatologic Agents